| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
116.21(B) |
| Last
Volume: |
1,379,606 |
Avg
Vol: |
1,610,683 |
| 52
Week Range: |
$323.57 - $450.8 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
23,137 |
144,475 |
259,873 |
619,971 |
| Total Sell Value |
$10,319,530 |
$60,539,246 |
$102,205,755 |
$209,876,745 |
| Total People Sold |
7 |
12 |
14 |
18 |
| Total Sell Transactions |
7 |
40 |
65 |
130 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Arbuckle Stuart A |
EVP, COO |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,221 |
96,252 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,272 |
67,270 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,452 |
77,964 |
|
- |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
24,322 |
70,412 |
|
- |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,026 |
72,890 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,568 |
68,645 |
|
- |
|
| Ambrose Kristen |
SVP & Chief Accounting Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,516 |
9,012 |
|
- |
|
| Biller Jonathan |
EVP and Chief Legal Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,293 |
11,587 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
68,478 |
158,076 |
|
- |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
76,578 |
79,001 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
26,400 |
79,752 |
|
- |
|
| Sachs Bruce I |
Director |
– • – |
2023-01-31 |
4 |
AS |
$325.01 |
$390,012 |
D/D |
(1,200) |
41,210 |
|
3% |
|
| Sachs Bruce I |
Director |
– • – |
2023-01-31 |
4 |
OE |
$72.14 |
$86,568 |
D/D |
1,200 |
42,410 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-01-31 |
4 |
AS |
$325.00 |
$34,450 |
D/D |
(106) |
37,998 |
|
3% |
|
| Carney Lloyd |
Director |
– • – |
2023-01-30 |
4 |
AS |
$320.08 |
$865,406 |
D/D |
(2,700) |
4,150 |
|
4% |
|
| Lee Yuchun |
Director |
– • – |
2023-01-27 |
4 |
AS |
$321.31 |
$460,177 |
D/D |
(1,429) |
1,875 |
|
1% |
|
| Lee Yuchun |
Director |
– • – |
2023-01-27 |
4 |
OE |
$72.14 |
$103,088 |
D/D |
1,429 |
3,304 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2023-01-26 |
4 |
AS |
$315.42 |
$1,273,322 |
D/D |
(4,000) |
1,875 |
|
3% |
|
| Lee Yuchun |
Director |
– • – |
2023-01-26 |
4 |
OE |
$72.14 |
$288,560 |
D/D |
4,000 |
5,875 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2023-01-25 |
4 |
AS |
$315.05 |
$3,150,500 |
D/D |
(10,000) |
89,598 |
|
6% |
|
| Lee Yuchun |
Director |
– • – |
2023-01-25 |
4 |
AS |
$312.80 |
$1,255,852 |
D/D |
(4,000) |
1,875 |
|
6% |
|
| Lee Yuchun |
Director |
– • – |
2023-01-25 |
4 |
OE |
$72.14 |
$288,560 |
D/D |
4,000 |
5,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2023-01-24 |
4 |
AS |
$312.29 |
$1,250,753 |
D/D |
(4,000) |
1,875 |
|
6% |
|
| Lee Yuchun |
Director |
– • – |
2023-01-24 |
4 |
OE |
$72.14 |
$288,560 |
D/D |
4,000 |
5,875 |
|
- |
|
| Lee Yuchun |
Director |
– • – |
2023-01-23 |
4 |
AS |
$312.02 |
$664,291 |
D/D |
(2,129) |
1,875 |
|
4% |
|
3274 Records found
|
|
Page 10 of 131 |
|
|
10.07 (2.2%) 
